Research for treatments, prevention and a cure
Page template: single-clinical-trials.php
Search terms : 

Clinical Trials

  • Clinical Studies

Clinical Management Science (CMS)

CTNPT 008: HIV quit smoking pilot study

Trial results

Print Friendly, PDF & Email


The rates of cardiovascular disease (CVD) are high among people living with HIV. Two of the factors thought to contribute to this inflated risk are increased smoking rates and the prevalence of depression in people living with HIV. Smoking is a direct risk factor for CVD and depression makes quitting smoking and remaining smoke-free more difficult. Therefore, the increase in depression and smoking rates may interact to increase the rates of CVD in people living with HIV. CTNPT 008 looked at the effectiveness of a counselling programme, in combination with nicotine replacement therapy (nicotine patch) to improve quitting rates. The counselling sessions focused on quitting smoking and addressing depression.

Study Population

Fifty participants were recruited from the Ottawa Hospital. Participants had to be a current smoker, willing to quit within 30 days, diagnosed with HIV, and currently on antiretroviral therapy.

Study Design

The study used a 24-week counselling design with a 6-month follow up. Counselling sessions occurred at baseline, quit date, and 4, 12, and 24 weeks after quitting. Abstinence from smoking was assessed using self-report questionnaires and biochemical measurement (exhaled carbon monoxide). Psychological and physiological measurements were repeated 6 months following the 24-week counselling period. Study participants were also given telephone-based support throughout the counselling period.

Results and Conclusions

At 6-month follow-up, 28% of participants demonstrated biochemically verified abstinence from smoking. This is considered a successful smoking intervention and compares well to other similar studies. At baseline, 52% of study participants showed signs of clinical depression. At 6-month follow-up, there was a trend towards a decrease in depression. Those with depression were not more likely to relapse back to smoking. This highlights the importance of including depression in counselling sessions to address this barrier to stopping smoking successfully. This pilot trial showed the importance of this type of program to help people with HIV quit smoking. 

Additional Information

Principal investigator

Dr. Louise Balfour
Ottawa Hospital and the University of Ottawa


Balfour L, Wiebe SA, Cameron WD, Sandre D, Pipe A, Cooper C, Angel J, Garber G, Holly C, Dalgleish TL, Tasca GA, MacPherson PA. An HIV-tailored quit-smoking counselling pilot intervention targeting depressive symptoms plus Nicotine Replacement Therapy. AIDS Care. 2017 Jan;29(1):24-31. Epub 2016 Jul 19.

Latest News

Why do we need PrEP Guidelines? Ask an expert. VIDEO

| Uncategorized | No Comments

Despite efforts to reduce new incidences of HIV like condom campaigns, needle exchanges, and treatment as prevention, the actual number…

Call for Nominations: Community Advisory Committee (CAC) 2018

| Uncategorized | No Comments

The CIHR Canadian HIV Trials Network (CTN/Network) is an innovative partnership funded by the Canadian Institutes of Health Research to…

Guest Blog: Dr. Nadine Kronfli on HCV treatment in Canadian prisons

| Hepatitis C | No Comments

Persons in custody in Canadian prisons have a 25-fold higher rate of hepatitis C (HCV) infection than the general population….

Guest Blog: CTN Postdoc Dr. Malika Sharma

| Uncategorized | No Comments

CTN Postdoctoral Fellow Dr. Malika Sharma writes about the current state of PrEP in Canada and how CTN 303 looks to change the way these HIV prevention drugs are delivered.

Research for treatments, prevention and a cure